STOCK TITAN

SS Innovations names Vishwajyoti P. Srivastava president

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

SS Innovations International, Inc. (SSII) appointed Gary G. Lo as Chief Financial Officer and Dr. Vishwajyoti P. Srivastava, previously Chief Executive Officer – Asia Pacific, as President, effective November 6, 2026. Lo’s agreement provides for $400,000 in annual base compensation, a target annual cash bonus of 50% of base salary subject to performance criteria, and options for 500,000 shares at an exercise price of $2.11 per share. The options vest in four annual installments beginning on the first anniversary, subject to continued employment, and expire ten years after the effective date. If terminated without Cause, subject to a release, Lo is eligible for three months of base salary in severance before the first anniversary or six months on or after it.

Srivastava’s base salary increased to $500,000 in connection with his appointment and relocation to the United States. He will oversee efforts to obtain U.S. and European Union marketing approvals for the SSi Mantra robotic surgical system and prepare for entry into those markets after approval. The company disclosed that it is responding to FDA queries during review of its 510(k) premarket notification and continuing toward CE marking in the EU. Srivastava is the son of Chairman and Chief Executive Officer Dr. Sudhir Srivastava; the company said it is negotiating other terms of a new employment agreement with him.

Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Gary Lo annual base compensation $400,000 Under his employment agreement effective November 6, 2026
Annual cash bonus target 50% of base salary Subject to performance criteria and the employment agreement
Options to purchase common shares 500,000 shares Grant under the company’s 2026 Incentive Stock Plan
Option exercise price $2.11 per share Options granted to Gary G. Lo
Option vesting installments Four annual installments Beginning on the first anniversary of the effective date, subject to continued employment
Option term Ten years From the effective date
Severance eligibility Three months or six months of base salary For termination without Cause, subject to a release; three months before the first anniversary and six months on or after it
Dr. Srivastava base salary $500,000 Authorized in connection with his appointment as President and relocation
510(k) premarket notification regulatory
"review of our 510(k) premarket notification"
A 510(k) premarket notification is a regulatory submission to the U.S. Food and Drug Administration that shows a new medical device is as safe and effective as an existing, legally marketed device. Think of it like demonstrating your new model performs like a trusted older model so it can be sold; for investors, 510(k) clearance is a key hurdle that affects how quickly a device can reach market, development cost, and the level of regulatory risk in a medical-device investment.
CE marking certification regulatory
"pathway toward CE marking certification in the European Union"
A CE marking is a regulatory stamp placed on a product to show it meets European safety, health, and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark is like a passport for market access: having it reduces regulatory risk, enables sales in a large market, and can affect costs, timelines, and legal exposure if the company must rework products to gain or maintain certification.
fair market value financial
"fair market value as defined in the Incentive Plan"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
at-will regulatory
"employment under the Employment Agreement is at-will"
vesting financial
"vest in four annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
severance financial
"eligible for severance equal to three (3) months"
Severance is the payment and benefits an employer provides to an employee when their job ends, acting like a short-term financial safety net or final paycheck plus extras such as healthcare continuation or stock vesting. Investors care because severance obligations are real costs and potential liabilities that can reduce cash, affect reported profits, and signal how a company handles leadership changes or downsizing, which can influence future performance and shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What regulatory work will SSII’s new president oversee?

Dr. Vishwajyoti P. Srivastava will oversee efforts to obtain U.S. and EU marketing approvals for the SSi Mantra and prepare the company for entry into those markets after approval. The company said it is responding to FDA queries during review of its 510(k) premarket notification and continuing toward CE marking certification in the EU.

What compensation did SSII set for its new CFO, Gary G. Lo?

Gary G. Lo’s agreement provides for $400,000 in annual base compensation and a target annual cash bonus of 50% of base salary, subject to performance criteria. It also provides for options to purchase 500,000 common shares at an exercise price of $2.11 per share, subject to the agreement and the company’s incentive plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001676163 0001676163 2026-11-06 2026-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 6, 2026

 

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Florida   001-42615   47-3478854
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

405, 3rd Floor, iLabs Info Technology Centre

Udyog Vihar, Phase III

Gurugram, Haryana India

  122016
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +91 73375 53469

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
Common Stock   SSII   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of new Chief Financial Officer

 

Effective November 6, 2026, Gary G. Lo joined the Company as its new Chief Financial Officer. Mr. Lo will be based in the United States. Mr. Lo, 56, has more than three decades of financial and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology businesses. Prior to joining the Company, from January 2026 to March 2026, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology company developing a bidirectional brain-computer interface. He previously served as Chief Financial Officer of Beyeonics Vision, a commercial-stage medical technology company developing a fully digital microscope for ophthalmic surgery, from March 2025 to December 2025. From January 2022 to July 2024, he served as Vice President of Finance and subsequently Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing robotics company, where he oversaw finance, accounting, investor relations, human resources, procurement and information technology and led the company’s $255 million Series C financing in August 2023. From January 2018 to December 2021, Mr. Lo served as Vice President of Finance for Legrand’s Building Control Systems division, a global business with operations in North America and Asia. From 2014 to 2017, he served as Vice President of Business Development (M&A) and IT at Sparta Systems, and from 2013 to 2014, he served as Chief Financial Officer of 1WorldSync, a global cloud-based product data management company. Previously, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson from 2003 to 2013, including Finance and IT Director for Vision Care Asia Pacific, as well as finance leadership positions at Siebel Systems from 2000 to 2003 and Boston Scientific from 1996 to 2000. Mr. Lo began his career as a senior auditor at PwC, where he worked from 1992 to 1996. A CPA, he holds a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting, magna cum laude, from Boston College.

 

The Company and Mr. Lo entered into an employment agreement (the “Employment Agreement”) effective November 6, 2026 (the “Effective Date”). Mr. Lo’s employment under the Employment Agreement is at-will. The Employment Agreement provides for annual base compensation of $400,000. Mr. Lo will be eligible for an annual cash bonus with a target amount of 50% of his base salary, based on achievement of certain performance criteria and subject to the terms of the Employment Agreement. In addition, the Employment Agreement provides for Mr. Lo to receive a grant of options under the Company’s 2026 Incentive Stock Plan (the “Incentive Plan”) to purchase 500,000 shares of the Company’s common stock. The options will vest in four annual installments commencing on the first anniversary of the Effective Date, subject to Mr. Lo’s continued employment by the Company and the other terms and conditions of the Incentive Plan. The options will have an exercise price of $2.11 per Share (fair market value as defined in the Incentive Plan), and will expire ten (10) years from the Effective Date. If Mr. Lo’s employment is terminated by the Company without “Cause” (as defined in the Employment Agreement), and subject to his execution of a release, he will be eligible for severance equal to three (3) months of base salary then in effect if the termination occurs before the first anniversary of the Effective Date, or six (6) months of base salary then in effect if it occurs on or after the first anniversary of the Effective Date. Mr. Lo also entered into a Confidentiality, Non-Disclosure and Assignment of Inventions Agreement with the Company.

 

The above summary of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report and is incorporated herein by reference.

 

1

 

Appointment of Dr. Vishwajyoti P. Srivastava as President

 

Effective November 6, 2026, the Company appointed Dr. Vishwajyoti P. Srivastava, M.D., who had been serving as the Company’s Chief Executive Officer – Asia Pacific, as President of the Company. In connection with his appointment, Dr. Srivastava has relocated to the United States, where he will be based in Denver, Colorado. As President, Dr. Srivastava will oversee and coordinate the Company’s efforts to obtain regulatory approval to market its SSi Mantra robotic surgical system in the United States and the European Union. He will also prepare the Company to enter those markets following receipt of those approvals.

 

Biographical information regarding Dr. Srivastava is set forth in under the caption “Directors, Executive Officers and Corporate Governance” in Item 10 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 10, 2026.

 

Dr. Srivastava is the son of Dr. Sudhir Srivastava, the Company’s Chairman and Chief Executive Officer. There are no other family relationships among the Company’s executive officers and directors.

 

In connection with his appointment as President and relocation, the Board of Directors authorized an increase in Dr. Srivastava’s base salary to $500,000. The Company and Dr. Srivastava are also negotiating the other terms of a new employment agreement, which will be disclosed in and filed as an Exhibit to a Current Report on Form 8-K, when completed and executed.

 

On November 13, 2026, the Company issued a press release announcing the appointment of Mr. Lo and the promotion of Dr. Srivastava.

 

A copy of the press release is included as Exhibit 99.1 to this Current Report.

 

2

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Employment Agreement between SS Innovations International, Inc. and Gary G. Lo, effective November 6, 2026+
99.1   Press Release, dated November 13, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

+ Indicates management contract or compensatory plan or arrangement.

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 13, 2026 SS INNOVATIONS INTERNATIONAL, INC.
     
  By: /s/ Sudhir Srivastava
    Sudhir Srivastava, M.D.
    Chairman and Chief Executive Officer

 

4

Exhibit 99.1

 

 

SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion

 

Promotes Dr. Vishwa Srivastava to President and Appoints Gary Lo as Chief Financial Officer

 

FORT LAUDERDALE, Fla. – November 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Dr. Vishwa Srivastava previously served as the Company’s Chief Executive Officer – Asia Pacific. Both executives are based in the United States.

 

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “At this critical juncture in SS Innovations’ growth journey, we are excited to announce the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Vishwa has been instrumental in the development and growth of our Asia Pacific region, and we are confident in his ability to successfully build our US business and lead our global operations during the next phase of expansion.”

 

Dr. Vishwa Srivastava said, “We have established a leading position in our immense home market of India, and I look forward to working closely with the team to build the required infrastructure and operations to further increase the presence of our advanced, cost-effective SSi Mantra surgical robotic system in the United States and globally in preparation for expansion. On that note, we have been responding to all queries raised by the U.S. Food and Drug Administration during its review of our 510(k) premarket notification for the SSi Mantra and we are simultaneously continuing along the pathway toward CE marking certification in the European Union. Additionally, we have been working at our R&D facility in India finalizing a pipeline of future disruptive healthcare technologies that we plan to roll out in the coming months.”

 

Dr. Sudhir Srivastava continued, “Gary brings to SS Innovations more than three decades of financial leadership experience and a proven track record of driving profitable growth and value creation across a range of prominent technology companies, including in the medical technology sector. We expect to benefit from his capital markets expertise, multinational company experience, financial planning and analysis skills, and strategic acumen as we build a truly global organization.”

 

Mr. Lo said, “I am thrilled to be joining the SSi team and supporting its mission to democratize access to advanced surgical robotic care. I believe that the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user-friendliness, training capabilities, proven track record of clinical success, and cost efficiency all distinguish SS Innovations in a large and growing global market.”

 

About Mr. Lo

 

Gary Lo has more than three decades of financial and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology businesses. Prior to joining the Company, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology company developing a bidirectional brain-computer interface. He previously served as Chief Financial Officer of Beyeonics Vision, a commercial-stage medical technology company developing a fully digital microscope for ophthalmic surgery; Vice President of Finance and subsequently Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing robotics company; Vice President of Finance for Legrand’s Building Control Systems division, a global business with operations in North America and Asia; Vice President of Business Development (M&A) and IT at Sparta Systems; and Chief Financial Officer of 1WorldSync, a global cloud-based product data management company.

 

At the start of his career, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson, finance leadership positions at Siebel Systems and Boston Scientific, and a senior auditor role at PricewaterhouseCoopers. Mr. Lo is a licensed Certified Public Accountant (CPA). He earned a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting, magna cum laude, from Boston College.

 

 

 

About SS Innovations

 

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

 

About the SSi Mantra

 

The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related information, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5 mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.

 

Forward-Looking Statements

 

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

 

Investor Contact:

 

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878

kalle.ahl@theequitygroup.com

 

Devin Sullivan, Managing Director

T: (212) 836-9608

devin.sullivan@theequitygroup.com

 

Media Contact:

 

RooneyPartners LLC

Kate Barrette

T: (212) 223-0561

kbarrette@rooneypartners.com

 

 

Filing Exhibits & Attachments

5 documents

Keep reading